Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (321-330 of 484) with videos related to

Pageof 49
Sort By:
Journal of the National Cancer Institute|June 29, 2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
The Prostate|August 27, 2015
Processing of voided urine for prostate cancer RNA biomarker analysisSue-Ing Quek, Olivia M Wong, Adeline Chen, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
Journal of the National Cancer Institute|July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialTheodore M Brasky, Amy K Darke, Xiaoling Song, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Cancer Causes & Control : CCC|July 20, 2012
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Cathee Till, Charlotte A Gaydos, et al.
International Journal of General Medicine|July 16, 2011
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US populationSun Hee Rim, Ingrid J Hall, Megan E Fairweather, et al.
JCO Precision Oncology|November 5, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 TrialGopa Iyer, Catherine M Tangen, Michal Sarfaty, et al.
World Journal of Urology|October 21, 2010
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinionsScott D Ramsey, Steven B Zeliadt, Catherine R Fedorenko, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Pageof 49

Showing results (321-330 of 484) with videos related to

Sort By:
Pageof 49
Journal of the National Cancer Institute|June 29, 2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
The Prostate|August 27, 2015
Processing of voided urine for prostate cancer RNA biomarker analysisSue-Ing Quek, Olivia M Wong, Adeline Chen, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
Journal of the National Cancer Institute|July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialTheodore M Brasky, Amy K Darke, Xiaoling Song, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Cancer Causes & Control : CCC|July 20, 2012
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Cathee Till, Charlotte A Gaydos, et al.
International Journal of General Medicine|July 16, 2011
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US populationSun Hee Rim, Ingrid J Hall, Megan E Fairweather, et al.
JCO Precision Oncology|November 5, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 TrialGopa Iyer, Catherine M Tangen, Michal Sarfaty, et al.
World Journal of Urology|October 21, 2010
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinionsScott D Ramsey, Steven B Zeliadt, Catherine R Fedorenko, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Pageof 49